MK-677 (ibutamoren) does not have evidence supporting its use as a height-increasing drug. While it raises growth hormone and IGF-1 levels in the blood, those hormonal changes do not automatically translate into growing taller, and the compound has never been shown in clinical trials to match the growth rates achieved by actual growth hormone injections. For adults, the question is largely moot because the cartilage structures responsible for bone lengthening have already disappeared, making additional height biologically impossible regardless of how much growth hormone circulates. The story is more nuanced for children and adolescents who still have open growth plates, but even there, the data are underwhelming.
What MK-677 Actually Does in the Body
MK-677 is an oral compound that mimics the hormone ghrelin. By activating ghrelin receptors in the brain, it tells the pituitary gland to release more growth hormone (GH). That burst of GH then triggers the liver and other tissues to produce IGF-1, a downstream hormone that mediates many of GH’s effects on growth and tissue repair. In animal studies, a single dose increased GH secretion roughly four- to tenfold depending on the dose, and IGF-1 levels rose and stayed elevated for up to two weeks of continuous treatment.1PubMed. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles In humans, a 25 mg daily dose produced roughly a 60% increase in IGF-1 at six weeks and about a 73% increase at 12 months.2PubMed. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial
The critical distinction is between raising hormone levels and actually getting taller. Growth hormone does many things in the body beyond bone lengthening. It influences muscle mass, fat metabolism, sleep architecture, and tissue repair. Elevating GH and IGF-1 does not selectively target height. And as we will see, the body has built-in feedback mechanisms that blunt MK-677’s hormonal effects over time.
Why Growth Plates Determine Everything
Height increases because of the growth plates, thin layers of cartilage near the ends of long bones. These plates contain stem cells that divide, stack up, enlarge, and eventually get replaced by hard bone. That process is what makes bones physically longer. Growth hormone plays a key role in regulating these cartilage stem cell populations and stimulating the chain of cell division and expansion that drives elongation.3PubMed Central. Growth hormone regulates the stem cell population in the growth plate
The catch is that growth plates have a built-in expiration date. As you go through puberty, the stem cells in the resting zone gradually get used up. The number of dividing cells decreases, the enlarging cells shrink, and eventually the whole cartilage structure gets replaced by solid bone. Once that closure is complete, no amount of growth hormone can reopen it or restart bone lengthening.4Clinical and Experimental Pediatrics. Growth plate closure and therapeutic interventions For most people, this happens somewhere between ages 14 and 18, though it can extend into the early twenties in some cases. A simple X-ray of the hand or wrist can tell a doctor whether your growth plates are still open.
If you are an adult reading this and your growth plates are closed, MK-677 cannot make you taller. Full stop. The machinery for bone elongation no longer exists, and circulating growth hormone has no target to act on for that purpose. This biological reality applies equally to MK-677, injectable growth hormone, or any other GH-boosting compound.
What the Pediatric Trials Actually Showed
The most relevant evidence for whether MK-677 can increase height comes from trials in children with growth hormone deficiency, the population where boosting GH should matter most. The results were not encouraging. In a six-month study, children treated with a related oral GH secretagogue (LUM-201, which works through a similar mechanism) grew at about 6 to 7 centimeters per year, compared to 4.5 cm/year in the placebo group. That sounds like a meaningful bump until you compare it to standard GH injections, which produced growth rates of about 11 cm/year.5PubMed Central. Treatment of Pediatric Growth Hormone Deficiency With Oral Secretagogues Revisited
MK-677 specifically was studied in children with GH deficiency in the late 1990s. When all the children’s data were combined, daily GH injections were clearly superior to once-daily oral ibutamoren for increasing growth velocity over six months. The gap was especially large for children with severe deficiency. Among children with moderate deficiency, the difference between MK-677 and injected GH was not statistically significant, but that is a narrow subgroup finding, not a ringing endorsement.6PubMed Central. Corroboration of Height Velocity Prediction Markers for rhGH With an Oral GH Secretagogue Treatment in Children With GHD A re-examination of that same data in 2018 confirmed the original conclusion: MK-677 simply did not perform well enough to compete with injectable GH as a treatment for short stature.
This is the core of why MK-677 never advanced through drug approval for growth purposes. An oral pill would have enormous practical advantages over daily injections for children, but regulators need a drug to actually work. MK-677 raised hormone levels without delivering proportional growth. That disconnect between hormone numbers and real-world height gain is the central problem.
The Feedback Loop That Limits MK-677’s Effect
One reason MK-677 may underperform is that the body actively fights back against sustained GH elevation. In a rat study, the initial GH response to MK-677 was robust, but by six weeks of daily treatment, the GH response was completely abolished. The cause appeared to be a sharp increase in somatostatin, the brain’s natural GH-suppressing hormone. Somatostatin production in the hypothalamus went up markedly, essentially creating a biochemical brake on GH release that negated MK-677’s stimulatory effect.7PubMed Central. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats
A similar pattern showed up in the beagle studies, where the GH response dropped 41 to 77% with repeated dosing, even though IGF-1 remained elevated.1PubMed. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles This presents a frustrating situation for anyone hoping to use MK-677 long-term: the hormone numbers look good on paper (IGF-1 stays up), but the pulsatile GH release that actually drives growth plate activity fades substantially. Injectable GH bypasses this feedback loop because it delivers the hormone directly rather than asking the pituitary to produce more.
This feedback attenuation is not something you can easily outsmart by cycling doses or adjusting timing. The body’s somatostatin system evolved specifically to prevent chronically elevated GH, which in excess causes serious health problems. The system works as designed, and that design limits MK-677’s practical utility for growth.
Bone Turnover Is Not the Same as Getting Taller
If you have researched MK-677 online, you have probably encountered claims about its effects on bone. Those claims have some scientific backing, but they do not mean what most people think they mean. In a study of obese young men, eight weeks of MK-677 treatment increased several markers of bone formation by 15 to 28%, alongside a roughly parallel increase in markers of bone resorption (the breakdown and recycling of old bone).8PubMed. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males Similar findings appeared in elderly subjects, where nine weeks of treatment raised bone formation markers by about 29% and resorption markers by about 23%.9PubMed. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults
Increased bone turnover means bones are being broken down and rebuilt faster. That can be relevant for bone density and fracture risk, but it is an entirely different process from longitudinal bone growth. Adults with closed growth plates remodel their existing bones constantly without getting any taller. The fact that MK-677 speeds up this remodeling cycle tells you something about its biological activity but nothing about height.
In postmenopausal women with osteoporosis, combining MK-677 with the bone drug alendronate did produce a modest improvement in femoral neck bone density (about 4.2% versus 2.5% for alendronate alone), but this benefit did not extend to the spine, total hip, or whole body.10The Journal of Clinical Endocrinology & Metabolism. Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women Even as a bone density treatment, MK-677’s track record is modest.
Side Effects Worth Knowing About
MK-677 is not a benign supplement, despite how casually it gets discussed in fitness communities. In a two-year trial of healthy older adults, the MK-677 group saw average fasting blood glucose rise by about 5 mg/dL, and insulin sensitivity decreased.11PubMed Central. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial That might sound small, but for anyone with borderline blood sugar or a family history of diabetes, pushing glucose levels in the wrong direction over months or years adds up. Growth hormone is inherently counter-regulatory to insulin. Any compound that raises GH is likely to impair glucose metabolism to some degree.
One reassuring finding is that MK-677 does not appear to elevate cortisol or prolactin with sustained use. A study of volunteers given MK-677 for seven days found no significant increase in either hormone compared to placebo.12The Journal of Clinical Endocrinology & Metabolism. MK-677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism Other commonly reported side effects include increased appetite (predictable, given that it mimics ghrelin, the “hunger hormone”), water retention, and joint stiffness. Increased appetite can be a significant practical problem for people not trying to gain weight.
For adolescents considering MK-677, the risk calculus is even less favorable. Manipulating growth hormone levels during puberty without medical supervision could theoretically accelerate growth plate closure, disrupt the timing of sexual maturation, or worsen insulin resistance during a period when the body is already undergoing major hormonal shifts. None of these risks have been systematically studied with MK-677 in healthy adolescents, which itself is a reason for caution.
What MK-677 Does Do Well
If the evidence against using MK-677 for height is fairly clear, its effects on sleep are one area where the data are genuinely interesting. In a placebo-controlled study, young subjects given high-dose MK-677 experienced roughly a 50% increase in deep sleep (stage IV) and a 20% increase in REM sleep. Older adults saw a similar jump of about 50% in REM sleep along with reduced REM latency, meaning they fell into dream sleep faster. Deviations from normal sleep patterns also dropped substantially in both age groups.13PubMed. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man
Better sleep is relevant to growth in children because the largest natural pulses of growth hormone occur during deep sleep. But improving sleep quality is a long way from increasing height. There is no evidence that MK-677’s sleep benefits lead to measurable increases in growth rate, and there are far safer ways to improve sleep hygiene.
What Actually Works for Short Stature in Children
For children who are genuinely short for their age and concerned about final adult height, the evidence-based path runs through a pediatric endocrinologist, not an online supplement vendor. In the United States and several other countries, recombinant growth hormone injections are approved for children shorter than about 2.25 standard deviations below the mean, which roughly corresponds to the shortest 1-2% of children for their age. This includes children with confirmed GH deficiency and, in some countries, children with idiopathic short stature (meaning they are short without an identifiable hormonal cause).14The Journal of Clinical Endocrinology & Metabolism. Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature
Even with approved GH treatment, the height gains are often more modest than families hope. A typical course of treatment might add a few centimeters to final adult height, not a dramatic transformation. Psychological counseling is considered a worthwhile alternative or complement to hormone treatment, since the distress around short stature often outweighs the actual functional limitation. These recommendations come from a consensus of the major pediatric endocrine societies, and they reflect the reality that even the best available growth treatments are incremental, not transformative.
The Online Market Problem
MK-677 has never been approved by the FDA for any indication. It remains an investigational compound, which means it cannot be legally sold as a drug or marketed with therapeutic claims. Nevertheless, it is widely available online, sold as a “research chemical” or buried in supplement branding. The quality control in this space is essentially nonexistent. Analysis of bodybuilding supplements marketed online has found that products frequently contain little or no active compound at all, and what is in the bottle may not match what is on the label.15Performance Enhancement & Health. The wild west of bodybuilding supplements: Three examples of unregulated compounds widely marketed online
This creates a particularly dangerous situation for teenagers or young adults buying MK-677 in hopes of gaining height. You may be taking an underdosed product that does nothing, an overdosed product that worsens your metabolic health, or something contaminated with an entirely different compound. There is no regulatory body checking these products before they reach you, and no reliable way to verify what you are actually ingesting without independent lab testing.
When Elevated IGF-1 Becomes a Concern Rather Than a Goal
The internet growth-hacking community tends to treat rising IGF-1 numbers as an unambiguous win. But chronically elevated IGF-1 is associated with its own set of health risks. Epidemiological research has linked persistently high IGF-1 levels to increased risk of certain cancers, particularly colorectal and prostate cancer. This is not a concern unique to MK-677; it applies to any intervention that keeps IGF-1 elevated above normal ranges for extended periods. The 12-month data showing a sustained 73% increase in IGF-1 from MK-677 is a double-edged finding.2PubMed. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial That level of sustained elevation was in older adults being studied for Alzheimer’s disease, and the trial found no clinical benefit from MK-677 for cognitive outcomes, despite robust IGF-1 increases. Hormones going up and clinical outcomes improving are two very different things, and MK-677’s history is one of consistently demonstrating the first while failing to deliver the second.
For a young person whose growth plates are still open, the relevant question is not “will MK-677 raise my IGF-1?” (it likely will), but “will that raised IGF-1 translate into more height than I would have reached naturally?” The pediatric trials suggest the answer is “not much, and certainly less than injectable GH.” For an adult, the question is simpler: raised IGF-1 cannot reopen closed growth plates, so the height benefit is zero while the metabolic and cancer-risk concerns remain. The risk-benefit math does not work out for either group when the goal is strictly to get taller.